跳到正文
原文
MedPage Today·· 4 天前AI 评分42

MRD能否引领多发性骨髓瘤的治疗决策?

MRD Ready to Guide Multiple Myeloma Treatment Decisions?

AI 导读

在即将召开的美国血液学会(ASH)年会上,专家圆桌讨论指出MRD已成为多发性骨髓瘤的重要预后工具,可预测无进展与总生存期并已影响FDA加速审批决策。专家强调MRD不能单独指导治疗,须结合基因组风险状态综合判断,FORTE试验显示5年持续MRD阴性获最佳PFS,DRAMMATIC研究正探索MRD阴性患者停药时机。

正文

— "MRD is becoming a very valuable tool, but it's not an exclusive tool," says expert

by Gregory Laub, Senior Director, Video, MedPage Today

November 16, 2026 • 5 min read

As minimal residual disease (MRD) testing becomes increasingly important in multiple myeloma care, questions remain about whether MRD negativity should guide decisions on treatment duration and the need for stem cell transplantation.

Heading into the American Society of Hematology annual meeting, MedPage Today brought together three expert leaders in the field: Moderator Joseph Mikhael, MD, is joined by Amrita Krishnan, MD, and Tulio Rodriguez, MD, all of the City of Hope, for a roundtable discussion. In this second of five exclusive episodes, the panel explores how MRD status, along with genomic risk and other patient factors, may influence treatment decisions.

Click here to watch all episodes of this roundtable series.

Following is a transcript of their remarks:

Mikhael: Let's move on to a discussion around, is it really time for MRD to guide our treatment decisions? Minimal residual disease negativity we know is prognostic. We know that it often predicts progression-free and overall survival, but are we at a stage where we're starting to pull the trigger and say the depth of someone's response based on MRD negativity is going to influence my treatment choice?

We'll talk later about the fact that MRD is now even influencing the FDA to allow us to accelerate approval of drugs, which I think is a great thing. But at the same time, we don't want to make decisions too prematurely. We don't want to make decisions... we don't want to wait and have people on treatment forever. So we've discussed in a previous roundtable the notion of the ENDURANCE trial and how it influences potentially the length of therapies, this idea that you got to take it forever.

I think of a colleague of mine who will remain nameless who made a license plate called REV4ever once. But have those days -- I'll start with you, Amrita -- have those days passed? Are you now saying to yourself, "I'm not sure that I just need to keep someone on treatment forever because maybe they're not going to get any more response after 2 years and maybe their immune system is not really going to be altered after 2 years." How are you approaching MRD guiding at least the length of therapy?

Krishnan: Don't you have a colleague who also has an MRD negative license plate, Joe?

Mikhael: Yes. That's my other colleague. That's right. Yes.

Krishnan: So I think first of all, caveat this with risk status also matters. So nothing exists in isolation. So you have to look at genomic risk status, probably also other functional risk status, as well as someone who has extramedullary disease or other high-risk features will play into this role of when you make that decision. So I would say in a standard-risk patient, one does feel more comfortable about using MRD negative and you can decide how many of those do you really need to be comfortable.

I would say probably more than one because you also want this idea of sustained MRD negativity, and that's where it becomes how many years do you want it sustained for? We have multiple trials looking at various timelines. I mean, if you want to wait for FORTE, that was 5 years of sustained MRD negativity really had the best outcome in terms of progression-free survival, but I don't think anyone wants to wait 5 years.

So I think most of us are comfortable with a minimum of 2, perhaps some of us want at least 3. The DRAMMATIC study at 2 years randomizes people who are MRD negative to stopping maintenance or continuing maintenance. So that may give us some hints as well. I think the bigger challenge is, quite frankly, people who are persistently MRD positive. There haven't been any good trials to really address what to do there.

Mikhael: Yeah, no, I agree with you. I think the idea is, as I look at it, is it's very important also to listen to our patients. A lot of our patients do have challenging side effects, and I think this helps us ensure that we don't let patients continue having diarrhea for years or weakness or fatigue, some of the things that we're having that high-risk patients may be thought about differently. And patients with persistent MRD positivity, as you've said, have to be thought about differently.

Although I'll always say there's that 5-7% of patients who will never achieve MRD negativity but actually do extremely well. The often hyperdiploid low-risk, if I can use that word, patient. I always say that as a caveat because I don't want people to think it's MRD or bust in everybody because some patients will live very long and do very well.

Tulio, if I could turn it a little bit for you, we know how much you've been involved in transplant for more than a couple of years. I'll be gentle for those of us with a little bit more gray hair in the room. But Tulio, we had some really remarkable data from our French colleagues in the MIDAS trial who took patients who received a quadruplet and then determined if they became MRD negative, they randomized them to either have a transplant or just continue the quadruplet. At least initially there doesn't seem to be a difference between those two arms.

Do you think MRD negativity, we've been talking about maintenance therapy, but even earlier on, do you think MRD negativity is going to guide whether we take patients to transplant or not?

Rodriguez: Yes, but not in isolation, as we have been discussing in other settings, in where you take a high risk versus standard risk or the genomic risk, for example, I think that that is going to play a role. For example, one of the European groups showed in extramedullary multiple myeloma where actually they went for tandem transplantation even after induction. I think that we will be more selective in who will need a stem cell consolidation and MRD will play an important role, but again, it's going to depend on staging, genomic risk, persistence of that MRD.

And something that sometimes we don't mention too often, but in my case, I have had patients in whom achieving that MRD might take a little bit longer than in others. And for those patients, I feel sometimes uncomfortable stopping maintenance right away, even after stem cell therapy.

Mikhael: Wonderful. So as we know, we can't in a short discussion answer all the questions, but if I'm hearing both of you correctly, whether it's early on in determining eligibility or need for stem cell transplant or length of therapy and maintenance, MRD is becoming a very valuable tool, but it's not an exclusive tool. It has to be put in the context of risk status, other features of the patient, obviously patient preference, but I do think we're going to see more and more use of MRD negativity influencing us as we treat multiple myeloma.

Thank you both for your input for this discussion around MRD guidance, and I'm looking forward to the next time we discuss it because I know we'll have even more data and evidence to guide what we're doing.

来源:MedPage Today · medpagetoday.com